GOOD MORNING TO... ☀️
The person who has been doing everything right on their GLP-1 and still feeling a little off. We see you. There is a very good chance you are not eating enough protein, and we are going to fix that today.
TL;DR ⚡
Four major medical organizations published the first official nutrition advisory for GLP-1 users. The protein target is higher than most prescribers mention.
A landmark NEJM head-to-head trial confirmed tirzepatide (Zepbound/Mounjaro) beats semaglutide (Ozempic/Wegovy) by nearly 50% for weight loss at 72 weeks.
Starting July 1, Medicare will cover Wegovy and Zepbound at $245/month with copays capped at $50. The biggest U.S. access expansion yet.
GLP-1 use was linked to a 14% lower risk of substance use disorders across alcohol, cannabis, cocaine, nicotine, and opioids in a study of 600K+ patients.
THIS WEEK'S BIG STORY 🔍
The Protein Gap Sabotaging Your GLP-1 Results
Something nobody warned you about when you started your GLP-1: not all the weight coming off is fat.
Research consistently shows that up to 40% of weight lost on GLP-1 medications can be lean muscle mass. That is not a rounding error. Muscle is what keeps your metabolism running. It is what prevents the rebound everyone fears. It is what determines whether you end up toned or just smaller.
Here is the real problem. When your appetite is suppressed, eating adequate protein feels nearly impossible. And based on new data, most users are failing at this. Only 43% of GLP-1 users consume at least 1.2 grams of protein per kilogram of body weight daily, which is now the minimum most medical groups recommend.
💪 If you are losing weight but not protecting muscle, you are building a slower metabolism and a higher chance of regaining everything if you ever stop the medication.
Four major organizations put their names on a joint advisory in 2026: the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Their official target for GLP-1 users in active weight loss: 1.2 to 1.6 grams of protein per kilogram of body weight per day. For a 180-pound person, that is roughly 100 to 130 grams daily.
The practical challenge is real. Three moves that help on suppressed-appetite days: prioritize liquid protein (shakes, Greek yogurt, cottage cheese) when solid food feels like a struggle, eat protein before anything else at every meal, and front-load breakfast with at least 30 grams. A protein shake on a bad nausea day is not giving up. It is strategy.
WHAT PEOPLE ARE SAYING 💬
The protein conversation is all over GLP-1 spaces right now. TikTok dietitians who work specifically with GLP-1 patients are reporting that clients consistently underestimate their actual protein intake by 30 to 50 grams per day. The gap between "I eat pretty healthy" and "I hit my targets" turns out to be enormous.
On physician social accounts and patient advocacy forums, a pattern keeps coming up: prescribers are getting better at this conversation, but many patients still leave their first appointment with no specific nutrition guidance. The medication gets all the attention. The eating strategy gets almost none.
A recurring theme in patient communities: people who add a high-protein first meal, even a small one, report noticeably better energy and mood stability, especially in weeks 2 through 12 of treatment. The data on fatigue and under-eating connects here.
IN THE NEWS 📰
Tirzepatide beat semaglutide by 47% in the first randomized head-to-head trial. SURMOUNT-5, published in NEJM, showed 20.2% weight loss with Zepbound/Mounjaro vs. 13.7% with Ozempic/Wegovy at 72 weeks. Real-world 2026 data is tracking the same direction.
Eli Lilly's once-daily oral GLP-1 (orforglipron) is awaiting FDA approval in Q2 2026. Trials showed 11.2% weight loss at 72 weeks. A pill option matters enormously for patients who cannot or will not inject.
About 10% of people may carry a genetic variant causing GLP-1 resistance. A new study found this subset produces more GLP-1 naturally but does not respond to the medications properly. Researchers are calling it "GLP-1 resistance." If you feel like the drug is not working, this may be worth asking your doctor about.
CVS is excluding Zepbound starting July 1. If Zepbound is your medication and CVS is your pharmacy benefit manager, talk to your prescriber now. Prior authorization appeals and formulary exceptions are worth pursuing before the deadline.
GOOD NEWS 🌱
Medicare's GLP-1 Bridge program launches July 1, covering Wegovy and Zepbound at $245/month with patient copays capped at $50/month. This is the single largest U.S. access expansion for obesity medications to date. Medicaid coverage follows in May 2026 for participating states.
GLP-1 use linked to 14% lower risk of substance use disorders across alcohol, cannabis, cocaine, nicotine, and opioids. The study followed more than 600K U.S. veterans with type 2 diabetes. GLP-1 receptors exist in the same brain structures that govern reward and addiction. The signal keeps getting stronger.
An oral GLP-1 pill is on the verge of FDA approval this quarter. Eli Lilly's orforglipron clears the needle barrier entirely. If approved, it could double the pool of people willing to start treatment and meaningfully cut cost over time.
QUICK WIN 💡
Eat your protein before anything else at your next meal. Not after the salad. Not alongside it. Put protein on the fork first. When appetite suppression hits midway through eating and you stop, you will have already gotten the most important macronutrient. One meal. Try it today.
YOUR QUESTION, ANSWERED ❓
"Is it normal to feel more tired than usual on my GLP-1, especially the first few weeks?"
Yes, and it is very often a nutrition issue rather than a medication problem. When appetite drops sharply, total calorie intake drops with it. Under-eating triggers fatigue faster than almost anything else. Before adjusting your dose or pausing the medication, try adding a protein-rich snack in the morning and tracking what you actually eat for three days. Most people are surprised by how little they are taking in. Under-eating on a GLP-1 is far more common than over-eating.
DRUGS IN THIS ISSUE 💊
Semaglutide (Ozempic, Wegovy)
Tirzepatide (Mounjaro, Zepbound)
Orforglipron (Eli Lilly, pending FDA approval)
sideffx is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making any changes to your medication, diet, or exercise routine.
See you Thursday. 🥛
the sideffx team
